Targeted Therapies May Improve OS in NSCLC With EGFR, ALK Mutations
Patients with non–small cell lung cancer treated with targeted therapies experienced an overall survival benefit.
Patients with non–small cell lung cancer treated with targeted therapies experienced an overall survival benefit.
A 61-year-old man with chronic lymphocytic leukaemia maintained on oral venetoclax 400 mg daily presented to the emergency department with oral lesions, worsening lymphadenopathy, and…
Currently patients with a form of the disease which has spread to one or two other parts of the body are assumed to be resistant…
Radiotherapy can be used alongside hormone treatment, delaying the need for chemotherapy and therefore significantly protecting their quality of life for some patients with advanced…
A multipeptide vaccine combination approach with 12MP plus 6MHP vs 12MP plus tet extended overall survival in patients with stage IIB to IV melanoma.
No association seen for mAb during breastfeeding with infant hospitalization, systemic antibiotic use, developmental delay.
Eftilagimod alpha plus radiotherapy and pembrolizumab was safe and displayed initial activity in soft tissue sarcoma.
Acalabrutinib combination therapy elicits statistically significant improvement in progression-free survival for treatment-naive mantle cell lymphoma.
Darolutamide uptake in metastatic hormone-sensitive prostate cancer has become routine both in doublet and triplet regimens in community urology practices.
Despite improved survival rates and guideline recommendations, many eligible patients with metastatic Merkel cell carcinoma are not receiving immunotherapy.
TAR-210 was safe and showed promising clinical activity in patients with FGFR-altered high- and intermediate-risk non–muscle-invasive bladder cancer.